<DOC>
	<DOCNO>NCT02423525</DOCNO>
	<brief_summary>The purpose study try determine maximum safe dose afatinib administer people brain cancer . Other purpose study : - find effect ( good bad ) afatinib ; - see much drug get body collect blood cerebrospinal fluid use pharmacokinetic ( PK ) study ; - learn afatinib might affect growth cancer cell ; - look biomarkers ( biochemical feature use measure progress disease effect drug ) .</brief_summary>
	<brief_title>Safety Study Afatinib Brain Cancer</brief_title>
	<detailed_description>This open-label , single institution , Phase I 3+3 dose escalation study describe safety tolerability afatinib patient brain cancer fail prior therapy determine recommend phase II dose . Eligible patient receive afatinib treatment cycle 28 day consist afatinib administer orally mouth every four day . Patients assign dose level open time enrollment . Patients continue dose afatinib disease progression , unacceptable toxicity , withdrawal consent , treat physician determines best interest stop . Guidelines modify study drug dos provide management adverse treatment effect . All patient regular evaluation assessment safety parameter detail study flow chart . Lumbar puncture blood draw assess afatinib level occur detail study flow chart . Neurological image assessment response perform approximately every eight week . Tumor response assess accord Response Assessment Neuro-Oncology ( RANO ) Working Group criterion . An end treatment evaluation occur patient permanently discontinue study drug , detail study flow chart . Patients follow every four month survival .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Histologically confirm diagnosis brain cancer : 1. glioblastoma ( GBM ) , 2. anaplastic astrocytoma ( AA ) , 3. anaplastic oligodendroglioma ( AO ) , 4. anaplastic mixed oligoastrocytoma ( AMO ) , 5. low grade glioma , 6. brain metastasis , 7. meningioma , 8. leptomeningeal metastasis 9. chordomas 10. pituitary tumor 11. medulloblastomas Has fail prior standard therapy include maximal safe surgical resection ( appropriate specific cancer type ) , radiation therapy ( appropriate specific cancer type ) , systemic therapy ( appropriate specific cancer type ) . For diagnosis GBM : undergone maximal safe surgical resection , course postoperative radiation therapy concurrent temozolomide , maintenance temozolomide . For diagnosis meningioma : option standard therapy surgical resection ( partial total resection ) radiation . Age 18 year old . Karnofsky Performance Status ≥ 60 % . Adequate organ function , define follow : 1 . Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L . 2 . Platelet count ≥ 100 x 109/L . 3 . Hemoglobin ≥ 9.0 g/dL . 4 . Total Bilirubin ≤ 1.5 institution 's upper limit normal ( ULN ) . 5 . Aspartate amino transferase ( AST ) ≤ 2.5 x institution 's ULN . 6 . Alanine amino transferase ( ALT ) ≤ 2.5 x institution 's ULN . 7 . Alkaline phosphatase ( ALP ) ≤ 2.5 x ULN unless consider tumor relate . Recovered previous therapyrelated toxicity Grade 1 clinical baseline study entry . Women childbearing potential negative serum urine pregnancy test initiation study drug dose . Insufficient time prior therapy study entry : 1. less 28 day wholebrain radiotherapy ( WBRT ) stereotactic radiosurgery ( SRS ) ; 2. less 28 day investigational agent ; 3. less 28 day prior cytotoxic therapy ( except 23 day prior temozolomide , 14 day vincristine ( GBM : 14 day irinotecan topotecan ) , 42 day nitrosoureas , 21 day procarbazine , irinotecan topotecan administration ) ; 4. less 14 day hormonal treatment 5. less 7 day noncytotoxic agent , e.g. , interferon , tamoxifen , thalidomide , cisretinoic acid , etc . 6 . When radiation necrosis suspect , standard care confirmatory imaging , MRI perfusion , magnetic resonance ( MR ) spectroscopy PET perform , patient find consistent radiation necrosis exclude . Current anticipated use enzymeinducing antiepileptic drug ( EIAED ) . Major surgery within 4 week start study treatment schedule surgery project course study . Known hypersensitivity afatinib excipients . History presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure New York Heart Association ( NYHA ) classification 3 4 , unstable angina poorly control arrhythmia , myocardial infarction within 6 month prior enrollment . Pregnant , nursing , use acceptable method birth control . Any history concomitant condition would compromise patient 's ability comply study interfere evaluation efficacy safety test drug . Previous concomitant malignancy site , except effectively treat nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ effectively treat malignancy remission 3 year consider cured . Known preexist interstitial lung disease . Known active hepatitis B infection ( define presence Hep B sAg and/ Hep B DNA ) , active hepatitis C infection ( define presence Hep C RNA ) and/or know HIV carrier . Prior participation blind afatinib clinical study , even assign afatinib treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>glioblastoma</keyword>
	<keyword>astrocytoma</keyword>
	<keyword>oligodendroglioma</keyword>
	<keyword>mixed oligoastrocytoma</keyword>
	<keyword>low grade glioma</keyword>
	<keyword>brain metastasis</keyword>
	<keyword>meningioma</keyword>
	<keyword>leptomeningeal metastasis</keyword>
</DOC>